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PENGARUH TEKNIK PROMOSI UBATAN ATAS KEPUTUSAN 
MEMPRESKRIPSI DALAM KALANGAN DOKTOR DI BANDAR SANA’A, 
YEMEN 
ABSTRAK 
 
Industri farmaseutikal melabur banyak dalam promosi dan ia menggunakan berbagai 
strategi promosi untuk mempengaruhi keputusan doktor untuk mempreskripsi. 
Tujuan kajian ini adalah untuk meneroka faktor-faktor yang digunakan untuk 
mempengaruhi keputusan doktor mempreskripsi dan peranan mereka dalam proses 
membuat keputusan. Khususnya, kajian ini menyiasat hubungan antara doktor dan 
wakil industri farmaseutikal dan untuk mengenal pasti persepsi doktor, kepercayaan 
dan sikap ke arah interaksi dengan wakil industri farmaseutikal tersebut, dan untuk 
meneroka faktor-faktor yang  berpotensi diubah suai yang mempengaruhi interaksi 
mereka; untuk mengenal pasti sumber utama maklumat doktor gunakan untuk 
mendapatkan pengetahuan mengenai ubat-ubatan baru dan untuk meneroka 
bagaimana mereka mempengaruhi keputusan doktor mempreskripsi; dan untuk 
menyiasat hubungan ciri-ciri doktor dan faktor penempatan amalan dengan faktor-
faktor yang lepas.  Kajian ini telah dijalankan menggunakan kaedah langkah demi 
langkah.  Dalam fasa pertama, kaedah kajian kualitatif telah digunakan untuk 
memahami secara mendalam fenomena berkaitan persekitaran dan sejauh mana 
masalah teknik promosi ubat. Dalam fasa kedua, kaedah kuantitatif, iaitu kajian 
keratan lintang telah digunakan. Kajian dilaksanakan di Sana’a, Yemen. Doktor  di 
hospital awam dan swasta telah diselidiki. Kesemua instrumen telah diuji ukuran 
kebolehkepercayaan dan kesahihannya. Analisis deskriptif dan inferensi termasuk 
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taburan frekuensi, peratusan, min (sisihan piawai), median (julat interkuartail), ujian-
ujian t sampel tidak bersandar, Mann–Whitney, analisis varians, Kruskal-Wallis, 
analisis faktor, dan analisis regresi linear berganda telah digunakan. Paras signifikan 
adalah 0.05.  Dapatan kajian fasa satu mendedahkan bahawa kebanyakan wakil-
wakil industri farmaseutikal yang ditemuramah tidak mempunyai pengetahuan 
mengenai tatakelakuan, dan penggunaan teknik-teknik promosi mereka yang berbeza 
bergantung pada strategi syarikat, pertimbangan dan/atau kemahiran mereka sendiri, 
dan tekanan daripada doktor dan jabatan jualan industri farmaseutikal. Kebanyakan 
doktor didapati menyambut baik kunjungan wakil penjual dan menganggap 
menerima sampel percuma, hadiah dan pelbagai sokongan sebagai amalan biasa. 
Walaupun doktor melaporkan kumpulan faktor yang mempengaruhi proses 
mempreskripsi seperti indikasi ubat-ubatan, sifat-sifat ubat, konteks pesakit, faktor-
faktor persekitaran dan pemasaran farmaseutikal, mereka masih bergantung kepada 
pengalaman peribadi mereka apabila membuat keputusan mempreskripsi. Selain itu, 
keputusan mereka untuk memilih ubat tertentu mungkin berdasarkan hubungan 
mereka dengan wakil syarikat dan aktiviti pemasaran firma.  Penemuan daripada fasa 
kedua kajian mendedahkan bahawa sebahagian besar doktor melaporkan telah 
menerima sampel ubat-ubatan (n=432, 96.2%), hadiah kecil (n=384, 85.5%) dan 
telah dijemput untuk seminar atau simposium oleh syarikat farmaseutikal (n=381, 
84.9%) dalam tempoh enam bulan sebelum menjawab soal selidik ini. Lebih 
daripada 80% (n=375; 83.5%) responden menganggap wakil syarikat sebagai satu 
cara yang berguna untuk belajar tentang ubat-ubatan baru, dan majoriti (n=383, 
85.1%) menegaskan bahawa mereka akan terus untuk bertemu dengan wakil 
syarikat. Selain itu, kekerapan lawatan wakil syarikat untuk doktor didapati berkaitan 
dengan pemberian barangan promosi yang lebih. Doktor yang mempunyai komitmen 
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pekerjaan lebih masa dan mempunyai kaitan akademik adalah lebih cenderung secara 
signifikan untuk menerima barangan promosi yang bernilai rendah.  Walau 
bagaimanapun, doktor lelaki, doktor am dan pakar yang mempunyai komitmen 
pekerjaan hari biasa dan mempunyai klinik swasta adalah jauh lebih cenderung 
secara signifikan untuk menerima barangan promosi yang bernilai tinggi. 
Kepercayaan doktor dalam kesesuaian penerimaan mereka terhadap item-item 
promosi, di samping, sikap terhadap syarikat-syarikat farmaseutikal telah didapati 
mempunyai peranan penting dalam meramalkan interaksi doktor dengan syarikat 
farmaseutikal (Adj. R2=0.208). Juga penemuan yang diperolehi daripada model 
regresi kajian ini mencadangkan bahawa, kepercayaan doktor dalam kesesuaian 
penerimaan mereka terhadap barangan promosi, interaksi dengan syarikat 
farmaseutikal, penerima barangan promosi bernilai rendah dan sumber maklumat 
langsung daripada syarikat mempunyai peranan dalam meramalkan keputusan 
mempreskripsi oleh doktor (Adj. R2=0.422).  Doktor mempunyai sikap yang 
bercampur-campur terhadap perkhidmatan maklumat yang disediakan oleh wakil 
syarikat. Majoriti doktor mempercayai bahawa kebanyakan teknik promosi tidak 
menimbulkan masalah etika utama. Kajian ini menjelaskan peranan syarikat-syarikat 
farmaseutikal dalam mempengaruhi keputusan mempreskripsi, dan meneroka 
pelbagai faktor yang berkaitan yang mempengaruhi proses membuat keputusan 
doktor. 
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THE INFLUENCE OF DRUG PROMOTION TECHNIQUES ON 
PRESCRIBING DECISIONS AMONG PHYSICIANS IN SANA’A CITY, 
YEMEN 
ABSTRACT 
 
The pharmaceutical industry invests heavily in promotion, and it uses a variety of 
promotional strategies to influence physicians’ prescribing decisions. The purpose of 
this study is to explore those factors used to influence physicians’ prescribing 
decisions and their role in decision-making process. Specifically, this study 
investigates the relationships between physicians and medical representative (MRs) 
and to identify physicians’ perceptions, beliefs and attitudes toward interactions with 
those MRs, and to explore the potentially modifiable factors influencing those 
interactions; to identify the main sources of information physicians use to obtain 
knowledge about new drugs and to explore how they influence physicians’ 
prescribing decisions; and to investigate the relationship of physicians’ 
characteristics and practice-setting factors with previous factors. This study was 
conducted in a step-wise approach. In the first phase, a qualitative research method 
was adopted to have an in-depth understanding of the phenomenon surrounding 
the nature and extent of drug promotion techniques. In the second phase, a 
quantitative method was applied using the cross-sectional. Research was conducted 
in Sana’a, Yemen. Physicians in public and private hospitals were surveyed. All 
instruments were tested for its reliability and validity measures. Descriptive and 
inferential statistical analyses including frequency distributions, percentages, means 
(sd), median (IQR), independent samples t-test, Mann–Whitney test, ANOVA, 
Kruskal-Wallis test, factor analysis, and multiple linear regression analysis were 
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applied. Level of significance (α) is equal to 0.05. Findings of phase one study 
revealed that most medical representatives interviewed did not have knowledge 
about any code of conduct, and their use of different promotional techniques depends 
on company’s strategy, their own judgment and/or skills, and pressures from 
physicians and pharmaceutical company sales departments. Most physicians were 
found to be welcoming representatives’ visits and consider receiving free samples, 
gifts and various kinds of support as a normal practice. Although physicians reported 
group of factors that influence the prescribing process such as drug indications, drug 
attributes, patient context, environmental factors and pharmaceutical marketing, they 
still rely on their personal experiences when making prescribing decisions. Further, 
their decisions to choose a particular drug may be based on their relationships with 
MRs and firms’ marketing activities. Findings from phase two of the study revealed 
that a high proportion of physicians reported having received drug samples (n= 432; 
96.2%), small gifts (n = 384; 85.5%) and having been invited to seminars or 
symposia by the drug company (n= 381; 84.9%) in the six months preceding the 
administering of the questionnaire. More than 80% (n=375; 83.5%) of the 
respondents considered the MRs to be a useful means of learning about new drugs, 
and majority (n=383; 85.1%) asserted that they would continue to meet with MRs. 
Moreover, the frequency of visits of MRs for physicians were found associated with 
provision of more promotional items. Those physicians who have overtime 
occupational commitment and have academic affiliation were significantly more 
likely to receive low-value promotional items. However, male physicians, GPs and 
specialists who have normal day occupational commitment and have private clinic 
were significantly more likely to receive high-value promotional items. The 
physicians’ belief in the appropriateness of their acceptance of those promotional 
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items, in addition to, attitude toward pharmaceutical companies were found to have 
significant role in predicting physicians’ interactions with MRs (Adj. R2 = 0.208). 
Also findings obtained from regression model of this study suggested that, 
physicians’ belief in the appropriateness of their acceptance of promotional items, 
interactions with MRs, receiver of low value promotional items and company-direct 
information sources have a role in predicting physicians’ prescribing decisions (Adj. 
R2 = 0.422). Physicians had mixed attitudes toward the informational services 
provided by MRs. The majority of physicians appeared to believe that most 
promotional techniques do not pose major ethical problems. This study clarifies the 
role of pharmaceutical companies in influencing prescribing decisions, and explores 
a variety range of related-factors that affects physicians’ decision-making process.  
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                                                 CHAPTER 1 GENERAL INTRODUCTION  
GENERAL INTRODUCTION 
 
1.1 Background  
 
Over the past two decades, interactions between physicians and the representatives of 
pharmaceutical companies have received increased scrutiny both within the medical 
field and among the public, as they create conflicts of interest which pose the risk of 
biasing physicians’ decisions in prescribing medications (Zipkin and Steinman, 
2005; Raad and Appelbaum, 2012). According to Gagnon and Lexchin (2008), 
pharmaceutical companies in the United States spent almost $57.5 billion on 
promotions, which amounts to approximately $61,000 per physician. Interactions 
between drug companies and physicians are pervasive and these interactions begin in 
medical school, continue throughout physicians’ residency training, and persist 
throughout a physician’s career (Blumenthal, 2004). These relationships take the 
form of advertisements, printed materials, contacts made by medical representative 
(MRs), gifts, samples, non-educational gifts (i.e., pens, mugs), educational materials 
such as textbooks, journals and reprints of industry publications, social events which 
may include meals and funding for travel or lodging to attend educational symposia, 
the sponsorship of physicians’ Continuing Medical Education (CME), honoraria, 
research funding, and even direct employment (Orlowski and Wateska, 1992; 
Wazana, 2000; Austad et al., 2011). One significant consequence of such 
relationships has been that they often result in a conflict of interests between a 
physician’s duties to their patient on the one hand and the pharmaceutical industry’s 
interest in maximising the sale of its products on the other, which may contribute to 
the over prescribing of medications and additional negative effects on patient health 
and the economy.(Gagnon and Lexchin, 2008). 
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Marketing is a common activity in business. The definition of marketing 
differs based on the opinions of the researcher. The most recent definition for 
marketing, released by the American Marketing Association (2008), includes the role 
marketing plays within society at large, and defines marketing as a science, an 
educational process and a philosophy—not just as a management system. “Marketing 
is the activity, set of institutions, and processes for creating, communicating, 
delivering, and exchanging offerings that have value for customers, clients, partners, 
and society at large” (Gundlach and Wilkie, 2009). 
Pharmaceutical marketing is the business of advertising or otherwise 
promoting the sale of drugs. The World Health Organization (WHO) defines 
pharmaceutical promotion as “all information and persuasive activities by 
manufacturers and distributors, the effect of which is to induce the prescription, 
supply, purchase and/ or use of medicinal drugs” (Norris et al., 2005). In this regard, 
the WHO and several NGOs are concerned with the unethical and inappropriate 
approach to the promotion of pharmaceutical products. At the 1997 roundtable on the 
WHO’s Ethical Criteria for Medicinal Drug Promotion, for instance, there was firm 
agreement among participants that the inappropriate promotion of medicinal drugs 
remained a problem both in developing and developed countries (World Health 
Organization, 1988). Apart from the concern over unethical and inappropriate drug 
promotion techniques, there has also been increasing concern over the irrational, 
inappropriate and, at times, harmful prescribing practices of physicians (Carthy et al., 
2000).  
The WHO’s code which governs the promotion of drugs unfortunately has 
not yet been implemented by most member countries; Yemen is one of them; as 
such, it has had a minimal impact on global standards of drug promotion. The 
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International Federation of Pharmaceutical Manufacturers’ code, compliance with 
which is essentially voluntary, has been proven to be ineffective (Joel Lexchin, 
1995).  As a result of such concerns, the efforts of pharmaceutical companies to 
promote prescription drugs have attracted the attention of policymakers, because 
such activities may affect the rate at which different drugs are prescribed and 
consumed, the total amount spent on health care and, ultimately, health outcomes. 
 
1.2 Country profile and pharmaceutical sector background 
 
Yemen is a medium size country with an area of 527,968 sq km. The country is 
situated in Middle East in the Southwest corner of the Arabian Peninsula, bordering 
the Arabian Sea, Gulf of Aden to the South, and Red Sea to the West, between Oman 
to the East, and Saudi Arabia to the North. The population of Yemen was estimated 
at 23,833000 in 2011. About 32% of total population are living in urban areas 
(MoPHP, 2011 ). 
Yemen is a low-income country, with a per capita Gross Domestic Product 
(GDP) of $926. The main natural resources of Yemen are petroleum, fish, rock salt, 
marble; small deposits of coal, gold, lead, nickel, and copper; fertile soil in West. 
Petroleum accounts for roughly 25% of GDP and 70% of government revenue. 
However, Yemen is facing difficult long term challenges, including declining water 
resources and a high population growth rate (MoPHP, 2011 ). 
Total expenditure on health as a percentage of GDP is 5.63%, while the 
budget of the Yemeni Ministry of Health, as a percentage of the government’s 
budget, is 3.58%; out-of-pocket expenditures on health-related services as a 
percentage of total health expenditures are 66.33% (MoPHP, 2011 ). Public health 
services are not free; the patient is expected to pay a prescription fee, the ex-store 
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cost of the medicines plus 10% and the cost of any required diagnostic tests (Al-
qubati and Ahmed, 2007) 
In Yemen, as in many other developing countries, public and private health 
services are primarily available in major cities. The annual statistical health report 
(2010) of the Ministry of Public Health & Population (MoPHP) shows a total of 
3,092 private pharmacies and a total of 5,974 physicians, including dentists (MoPHP, 
2010).  
The Yemeni pharmaceutical market is an open market overseen by the 
Supreme Board of Drug and Medical Appliances (SBDMA). In the last decade, the 
drug manufacturing industry in Yemen has experienced rapid growth; in 1990, there 
was one local pharmaceutical manufacturer, whereas there are currently nine 
manufacturers operating in the country. Local manufacturers account for only a small 
portion of the total market (6.85% in 2006 and 10.8% in 2010); medicines imported 
via private sector agents cover most of the country’s needs (approximately 85%). 
The number of registered medicines has reached 12,596 (Al-Hamdi et al., 2012). The 
Yemeni pharmaceutical market was estimated to be worth $297 million total as of 
2010, compared with a $70 million estimate as of 2000 (a compounded annual 
growth rate of 17.42%) (SBDMA, 2010) 
 
1.3 Problem statement  
The prescription drug market is unique in the sense that the end user is not the 
person tasked with choosing the product to be purchased, since it is the physician 
who is responsible for selecting the correct medication for patients from among the 
various available options. Companies therefore seek to direct their promotional 
efforts toward physicians in an effort to influence their choices, thus setting as the 
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primary purpose of promotion to increase sales, despite any negative effect doing so 
might have on patient health and the economy.  
In the specific context of Yemen, as has been mentioned earlier, there is 
significant increase in the numbers of registered drugs and as a consequence of this 
the competition among drug companies highly intensified. This has meant that there 
has been a greater need for more intensive marketing and expanded promotional 
activities. In this context, the contacts and relationships between the pharmaceutical 
industry and its representatives on the one hand and physicians on the other have 
been seen as a vital part of marketing and promotional activities. There are currently 
no national drug promotion regulations in Yemen, however, nor is there any clear 
mechanism by which to monitor the promotional activities of the pharmaceutical 
industry. Apart from the absence of any comprehensive regulations controlling drug 
promotion, there is also very little information regarding both the nature and extent 
of the interactions between pharmaceutical companies and physicians as well as the 
attitudes of physicians regarding such interactions. Similarly, little is known about 
whether these attitudes are present from an early stage or develop during the course 
of a physician’s career through the influence of the pharmaceutical companies. As a 
result of this lack of information, the drug promotion practices in Yemen and their 
impact on the prescribing decisions of physicians continue to remain a mystery to 
many stakeholders in the public health sector. 
Bearing in mind the above concerns, this study aims to investigate the nature 
and extent of the relationships between pharmaceutical companies and physicians in 
Yemen. In doing so, this study will focus on investigating Yemeni physicians’ 
sources of information regarding new drugs as well as drug promotion practices and 
their impact on physicians’ prescribing decisions in Yemen. 
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The objectives of this study are thus, first, to gain insight into the nature and 
extent of Yemeni physicians’ relationships with MRs and their influence on 
physicians’ prescribing decisions and, second, to develop models which are able to 
explain the potentially modifiable factors which influence physicians’ prescribing 
decisions. In order to achieve these objectives, this study will adopt a mixed-mode 
methodology of quantitative and qualitative approaches. 
 
1.4 Rationale for and importance of the study 
There are a number of reasons for concern over the impact pharmaceutical 
companies’ marketing strategies may have on a physician’s prescribing decisions. 
These include: (Buckley, 2004)  
• the fact that drug promotion is often misleading;  
• the risk of disease-related fear-mongering;  
• the increasing costs of drugs within the national health system; and,  
• the fact that new drugs are the ones most heavily promoted, and these are 
the ones with the least well-understood safety profiles.  
Interactions between physicians and the medical representatives (MRs) of 
pharmaceutical companies therefore raise a number of scientific and ethical 
questions.  
Thus, there is a need for more research regarding the causal relationships 
between pharmaceutical companies and physicians’ prescribing behaviours. Such a 
need is succinctly summarised in the WHO-sponsored review on drug promotion 
where Norrie and his associates (2005) found gaps in evidence regarding more high-
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quality studies which establishes causal relationship between drug promotional 
activities and attitudes and physicians’ prescribing behaviours, and they stressed for 
a need of qualitative studies exploring the relationships between physicians’ attitude 
towards pharmaceutical promotions and their other characteristics. They also 
highlighted in their review that all the previous evidence related to drug promotional 
studies, are from developed countries and there is lack of such study from developing 
countries (Norris et al., 2005).  
Gallan (2005) developed a general theoretical model of physicians’ 
prescribing behaviour in an outpatient setting, which was based upon the factors 
enumerated in the literature review. According to Gallan, the body of evidence 
pertaining to the factors which influence physicians’ prescribing of pharmaceuticals 
is relatively small, and more research is needed to better identify the correlation of 
factors and their effect on how physicians’ actually prescribe pharmaceutical 
products. (Gallan, 2004)  
Based on the above-mentioned scientific and ethical considerations and in the 
context of Yemen, it is imperative to conduct a comprehensive study which explores 
the potentially modifiable factors that influence both physicians’ interactions with 
MRs and physicians’ prescribing decisions, and which evaluates the possibility of 
using these factors to manage pharmaceutical companies’ promotional techniques 
through the development of appropriate models. 
In this regard, to the best of the researcher’s knowledge no study on the 
impact of drug promotion practices which focused in particular on the prescribing 
decisions of physicians has yet been conducted in the Yemeni context. This study 
through mixed-methods therefore aims to investigate the impact of the nature and 
8 
 
extent of the relationship between pharmaceutical companies and physicians in 
Yemen and will attempt to develop models capable of explaining the potentially 
modifiable factors which influence the prescribing decisions of physicians. 
 
1.5 Significance of the study’s findings 
The findings from the study conducted have several potential benefits as discussed 
below: 
1. This study findings will help to clarify the issues pertaining to 
pharmaceutical promotion techniques and how these affect prescribing 
practices in Yemen .The findings are expected to identify the benefits to 
the various parties in the pharmaceutical sector in Yemen, which include 
policymakers, the MoPHP, the SBDMA, physicians’ professional 
organisations, medical boards, individual physicians, health-related 
colleges, MRs and pharmaceutical companies. 
2. This information may prove important to currently practicing physicians 
who interact with pharmaceutical companies. Identifying the potential 
influences of pharmaceutical companies’ marketing techniques on their 
own prescribing practices will be important in order to make appropriate 
judgments about the information and compensation they receive from the 
pharmaceutical companies. 
3. The findings of this study will provide much-needed information for 
professional physicians’ organizations and medical boards as they attempt 
to develop and disseminate standards of care, professional guidelines and 
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scopes of practice, and may choose to develop guidelines which are 
related to physicians’ interactions with pharmaceutical companies. 
4. The findings of this study will provide much needed information 
regarding the nature and extent of MRs’ marketing techniques and their 
relationships with physicians, and the impact these factors have on 
physicians’ prescribing decisions. Such findings will allow policymakers 
in the public and private health sector in Yemen, and especially the 
SBDMA, to better manage and control the promotional activities of MRs 
and develop suitable policies and regulations pertaining to drug 
promotion, as well as to develop guidelines which set out what should be 
considered appropriate interactions between physicians and MRs, while 
seeking to diminish if not eliminate the apparent ethical conflicts of 
interest inherent to the relationship between the two sectors. 
5. The findings will provide insight into and a better understanding of intern 
and postgraduate students’ attitudes and behaviours in response to 
pharmaceutical promotions and the effect of physicians’ interactions with 
the representatives of a given pharmaceutical company. This information 
will be important to faculty members, as medical schools will then be able 
to address the issue of pharmaceutical companies’ influence over the 
curriculum, to prepare medical and postgraduate students to critically 
assess the information they receive from pharmaceutical sources while in 
training and their critical decision-making processes as they relate to 
prescribing medications in a clinical setting. 
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6. The findings of the study can make a significant contribution by 
identifying the factors potentially able to be modified which influence 
physicians’ interactions with MRs and their prescribing decisions. The 
findings of this study will be of great importance for industry 
organisations as they attempt to develop effective self-regulations and 
local codes of conduct and encourage the pharmaceutical companies to 
comply with the ethical marketing practices and self-regulation thus 
developed. 
7. This study will provide insight into those factors which influence 
physicians’ prescribing behaviour with regard to new-to-market drugs, 
which is important for understanding the role of pharmaceutical 
marketing in influencing prescribing decisions. The findings of this study 
will therefore be important to all stakeholder groups as they attempt to 
design and evaluate those interventions aimed at pharmaceutical 
promotion practices and effecting behavioural change among physicians. 
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1.6 Objectives  
The aims of this study are as follows: 
1. To identify the main sources of information physicians use to obtain 
knowledge about new drugs. 
2. To identify physicians’ perceptions, beliefs and attitudes toward 
interactions with pharmaceutical company MRs. 
3. To explore the potentially modifiable factors which influence 
physicians’ interactions with medical representatives. 
4. To explore the potentially modifiable factors which influence 
physicians’ prescribing decisions. 
5. To identify the relationship of physicians’ characteristics and practice-
setting factors  with their perceptions about the factors influencing 
their prescribing decisions, beliefs, attitudes toward interaction with 
MRs and sources of information.  
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1.7 Thesis overview 
Figure 1.1 shows the chapter-by-chapter content of this thesis, as well as the study 
phases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 1 Thesis overview flow chart 
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Chapter 1: Introduction 
• Problem statement.  
• Rational of the study.  
• Significance of the study 
• Study Objectives. 
 
 
 
 
 
 
Chapter 2: Literature review 
• Theoretical background 
• Previous study  
 
 
 
 
 
 
Chapter 3: Qualitative phase 
• Qualitative methodology  
• Result and discussion part 1 
 (MRs interviews) 
• Result and discussion part 2 
(Physicians interviews) 
• Result and discussion part 3 
(Physicians interview) 
• Chapter summary 
 
 
 
 
 
 
Chapter 4: Quantitative phase 
• Quantitative methodology 
(Physicians Survey) 
• Result part 1: Factors influencing physicians' 
interaction with MRs 
• Result part 2 : Factors influencing 
prescribing decision 
 
 
 
 
 
  
Chapter 6: Thesis conclusion and recommendation 
 
 
 
 
 
 
 
Chapter 5: Discussion (Quantitative phase) 
Part 1: Factors influencing physicians' 
interaction with MRs  
Part 2: Factors influencing prescribing decision  
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                                      CHAPTER 2  LITERATURE REVIEW 
LITERATURE REVIEW 
2.1 Introduction 
 The aims of this study are firstly to gain insight into the nature and extent of 
Yemeni physicians’ relationships with medical representatives (MRs) and their 
influence on physicians’ prescribing decisions and secondly to develop models 
which are able to explain the potentially modifiable factors which influence 
physicians’ prescribing decisions. 
The present chapter begins with an explanation of the concepts and 
terminology used in the research (section 2.2), with a brief general overview of the 
factors that influence physicians’ prescribing decisions (section 2.3) followed by a 
comprehensive review of the different sources of drug information and the role of 
industry sources in drug prescribing decisions (section 2.4). An overview of drug 
promotion is then presented, including a comprehensive review of physicians’ 
interactions with medical representatives and the attitudes and perceptions which 
result from their interactions with those medical representatives (section 2.5). After 
thoroughly reviewing all the factors influencing prescribing decisions, the theoretical 
background is explained (section 2.6). General conclusions are presented (section 
2.7). Based on the theoretical models reviewed through the previous sections, the 
conceptual framework of this study is developed (section 2.8), research questions are 
presented (section 2.9) and finally the hypotheses of the research are presented 
(section 2.10). 
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2.2 Concepts and terminology 
 
For a proper understanding of the information provided in this thesis, some of the 
terms and concepts are defined below. 
Pharmaceutical Medical Representatives: Their job is to meet individually with 
physicians and promote company products, visit physicians on a regular basis, over a 
week or month, promote a drug’s advantages and even push the physicians toward 
using their products (Al-Hamdi, 2012). Pharmaceutical detailing is a marketing 
technique used by pharmaceutical companies to educate a physician about a vendor's 
products in the hope that the physician will prescribe the company’s products more 
often (Rouse, 2011). 
Interns: Interns are physicians gaining supervised practical experience in hospital 
after graduating from medical school (Mari, 2008)  
General practitioners (GPs): Those physicians who have no additional 
qualifications after their graduation (MBBS) are classified as ‘general practitioners’ 
(GPs) (Mari, 2008). 
Residents: A resident is a physician serving a residency in which he or she obtains 
medical training and education. This normally follows graduation from medical 
school and becoming licensed to practice medicine. The resident completes his 
medical school training and/or an internship and goes through the process of 
receiving specialized training (Mari, 2008).  
Physicians: Physicians are skilled health care professionals trained and licensed to 
practice medicine. They are also known as doctors of medicine (Mari, 2008). 
Marketing: A business philosophy involving the expectation of the customer’s need 
and recognition of his problem, and thereafter fulfilling of these with products, 
services and information in a profitable way (Lexicon, 1998).  
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Theory of planning behaviour constructs  
Attitude:  Personal evaluation of behaviour. 
Subjective Norm: These are beliefs about whether key people approve/disapprove 
of the behaviour. 
Perceived Behavioural Control: The belief that one has and can exercise control 
over performing behaviour (Fishbein and Ajzen, 1975; Ajzen, 2005).  
 
2.3 An overview of the factors that influence physicians’ prescribing decisions 
Many studies have been conducted to explain the prescribing decisions of physicians 
and factors affecting their prescribing patterns. Various factors were mentioned in 
the literature which influence the prescribing decisions of physians. However, most 
of these studies were conducted in developed countries. One of these studies 
conducted in United Kigdom highlighted the importance of the pharmaceutical 
industry through their medical representatives in raising the awareness of new drugs 
and consequently affected the prescribing decision of physicians (Prosser et al., 
2003). Another study in the United Kingdom also cited commercial sources of 
information as a factor influencing prescribing decisions (Jacoby et al., 2003). 
Medical representatives were an important source of information about new drugs for 
physicians, which were also mentioned in a study conducted by Jones et al. (2001). 
There are few other considerable factors which affect the prescribing decisions of 
physicians such as detailing, direct contacts with MRs and promotional activities 
directed towards medical students and trainee physicians (Naik et al., 2009). 
However, drug companies do not only offer information to influence prescribing 
decisions, but also provide samples via MRs to influence the prescribing of new 
drugs (Tobin et al., 2008). Also, Pitt and Nel (1988) mention that promotional tools 
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and sales calls by MRs can be perceived as the most influential factors. However, 
contradicting this, a study mentioned that direct-to-consumer advertising, visual 
reminders (such as pens and drug samples) and the possession of honorariums were 
considered as having little or no influence on prescribing decisions (Nutescu et al., 
2005). The next stage of prescribing decisions is the evaluation of the drug, which 
involves multi-factorial influences from several sources. However, the most 
frequently cited influence was the medical representative (Prosser and Walley, 
2003a).   (Pitt and Nel, 1988) 
 Other factors influencing prescribing decisions mentioned in the literature 
generated in developed countries were drug attributes including efficacy, adverse 
drug events, safety, tolerability, cost, and the pharmacological functions of the index 
drugs (Freeman et al., 1993; Miren I. Jones et al., 2000; Jacoby et al., 2003; 
Buusman et al., 2007; Tobin et al., 2008; Theodorou et al., 2009; Tušek-Bunc et al., 
2010). Other researchers include the availability of drug samples, company 
marketing practices, levels of risk aversion, previous clinical experience with certain 
drugs, the improved regimens of drugs, as well as cost or drug price (Miren I Jones et 
al., 2001; Jacoby et al., 2003; Klein et al., 2006; Buusman et al., 2007; Ljungberg et 
al., 2007). Although many physicians consider the cost of the medicine to be a 
secondary factor affecting their prescribing decisions and they were more reluctant to 
prescribe new drugs due to the effects of increased pressure of drug and fund-holding 
budgets (Miren I Jones et al., 2001). Therefore, the price was considered to be an 
important factor by GPs (Buusman et al., 2007). In compliance with that, a study 
from UK explored cost effectiveness as the main reason behind the maximum use of 
lansoprazole rather than omeprazole from the general practitioner (Miren I Jones et 
al., 2001). Also,  many  consultants  reported  that  cost was a factor which 
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influenced their decision, with the exception of one respondent who stated  that cost 
was not a factor (Miren I. Jones et al., 2000). Other factors mentioned in the 
literature included formulary status, the drug’s efficacy and the presence of drug use 
restriction policies (Nutescu et al., 2005).  It was also mentioned that patient 
characteristics were found to be important considerations when physicians prescribe 
medication (Ljungberg et al., 2007). Among these were patient knowledge, patient 
convenience and the acceptability of the new drug, along with the patient’s economic 
level and social security (Prosser et al., 2003). Also an important character is patient 
expectation or a patient request for a drug (Theodorou et al., 2009; Tušek-Bunc et al., 
2010). It was reported in the literature that patient demand was one of the most 
common reasons given by physicians for use of drugs (Schwartz et al., 1989). 
However, patients requests for specific drug  were found to be inspired by direct-to-
consumer advertisements (Naik et al., 2009).  
An important factor influencing physicians’ prescribing decisions in 
developed countries is what is known as social knowledge or peer pressure (Tušek-
Bunc et al., 2010). This pressure was exerted in form of professional peers, pharmacy 
advisors, colleagues and/or specialists recommendation (Jacoby et al., 2003; 
Ljungberg et al., 2007; Tobin et al., 2008). Some researchers mentioned that 
recommendations made by colleagues in informal discussion are the second most 
important determinant in prescribing decisions (Pitt and Nel, 1988). Also, habit and 
peer pressure were blamed by physicians for their non-scientific prescribing 
(Schwartz et al., 1989). Department heads and colleagues in the same specialty were 
also mentioned as a factor affecting decisions about which drugs can be prescribed to 
patients (Kisa, 2006).  
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In addition to all above factors, a common factor reported in the studies 
conducted in developed countries was personal experience (Pitt and Nel, 1988; 
Schwartz et al., 1989; Nutescu et al., 2005; Prosser and Walley, 2006; Ljungberg et 
al., 2007). Hospital consultants and observation of hospital prescribing were cited the 
second most frequently (Prosser et al., 2003). Others groups included external factors 
such as independent written literature and health authority medical and pharmacy 
advisors or what they called scientific knowledge (Jacoby et al., 2003; Prosser and 
Walley, 2006).  
 When it comes to developing countries, a study conducted in Turkey revealed 
that, same as in developed countries, the majority of participants reported that MRs 
were the main information source regarding the new drugs launched onto the market  
(Kisa, 2006). According to another study, also conducted in Turkey, general 
practitioners (GPs) mentioned that their prescribing decisions were affected by their 
involvement in drug companies’ training activities as well as frequent visits by MRs. 
They also stated that the pharmaceutical companies’ drug guides were the most 
frequent sources used in case of any problems in prescribing decisions (Vancelik et 
al., 2007). In both Turkey and Slovenia, GPs mentioned that attitudes towards drug 
marketing and personal involvement in drug promotional activities were important 
influencing factors in prescribing decisions (Tušek-Bunc et al., 2010). Also, a recent 
study conducted in China by Weihui et al. (2011) systematically summarized various 
factors related to prescribing behaviour. According to that study, the factors that 
influence physicians’ prescription behaviour can be classified in seven ways: the 
physician factor, the patient factor, the disease factor, the prescription factor, the 
medicine supplier factor, the medicine factor and the policy factor. The most 
important influences on physicians’ prescribing behaviour were the physician factor, 
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the disease factor and the drug factor. However, the patient factor and policy factor 
were not included in the first ten influential factors (Weihui et al., 2011). 
 
 From a comprehensive analysis of above studies, the researcher found that 
both qualitative and quantitative studies addressed the issue of factors that influence 
physicians’ prescribing decision and that each of them looked at different aspects of 
the question. Often, the physicians’ prescribing decisions were assessed by using a 
self‐reporting survey questionnaire or an interview in the case of qualitative studies. 
Some qualitative studies focused on the reasoning behind initiating drug therapy and 
the prescribing decisions of new drugs launched in the market. Most reviewed 
studies suggested that prescribing decisions were multi-factorial and were often 
influenced by more than one factor. A lot of evidence generated from both 
qualitative and quantitative studies suggesting that pharmaceutical companies 
influence prescribing decisions of physicians through their medical representatives in 
terms of raising awareness of new drugs and other drugs promotion activities. 
 
2.4 Sources of drug information 
Prescribing is a very complex process that requires an informed decision about the 
medicine of choice for the treatment of a particular patient. Therefore, up-to-date, 
high quality information is a powerful tool for making it possible for physicians for 
better prescribing decisions in order to offer their patients optimal healthcare. The 
pharmacological basis of therapeutics prescription requires a complex array of 
information, and clinical decision making is assumed to be based on evidence-based 
medicine information resources. 
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The physicians depend on various sources of drug information (Oshikoya et 
al., 2011). A wide variety of sources of drug information are included in the literature 
such as pharmacists, colleagues, the British national formulary (BNF), information 
supplied by patients, the monthly index of medical specialties (MIMS), medical 
journals, the internet, direct  mail  advertising, symposia/conferences, free samples, 
medical representatives, literature from pharmaceutical companies, pharmaceutical 
company material, drug information centres (DICS)/ drug information units 
(hospital-based), medical books, drugs and therapeutics bulletins, journal 
advertisements, physicians’ desk reference, regular meetings at hospitals, domestic 
and international conferences, continuing medical education (CME), medical school 
lectures, sponsored meetings, professional contacts, national standard treatment 
guidelines and the extra pharmacopoeia (Strickland-Hodge and Jeqson, 1980; Peay 
and Peay, 1990; Verhoeven et al., 1995; Lundborg et al., 1998; McGettigan et al., 
2001; Spiller and Wymer, 2001; Layton et al., 2007; Rohra et al., 2007; Tumwikirize 
et al., 2007; Othman et al., 2009; Lua et al., 2011; Oshikoya et al., 2011). 
 
2.4.1 Classification of drug sources of information 
Sources of information are classified in the literature into two main categories; 
professional sources and commercial sources and others (Eaton and Parish, 1976; 
Peay and Peay, 1984; Peay and Peay, 1990). Also  Strickland-Hodge and Jeqson, 
(1980) categorized sources of information into professional and industrial, while 
each of these two categories were further categorized into ‘active’ information and 
‘passive’ information (industry active or passive and professional active or passive). 
A review of 17 studies was conducted by Williams and Hensel (1991) to explain the 
sources, importance and use of information about drugs by physicians. They 
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categorized the drug source of the information into two dimensions, personal/non-
personal and commercial/non-commercial. Personal variables included pharmacists, 
colleagues, detailing, and conferences /meetings/ conventions. Non-personal sources 
included journal articles, journal advertising, and direct mail. Commercial sources 
(i.e., marketer controlled) were defined as journal advertising, direct mail, and 
detailing. Non-commercial sources included journal articles, meetings, conventions, 
pharmacists, and colleagues. (Williams and Hensel, 1991) 
 
2.4.2 Availability and access to up-to-date drug information 
Sources used by doctors to find medical knowledge include textbooks, journals and 
electronic databases. However, doctors face the challenge of finding up-to-date 
information that satisfies the needs of their individual patients, and they may always 
be overwhelmed by the volume of information provided to them (Smith, 1996). In 
developing countries, medical representatives are commonly the sole source of 
information about drugs (Norris et al., 2005). A study in Uganda has revealed that all 
doctors in private, district, general and teaching hospitals were found to be deficient 
in terms of their access to current medical information due to problems such as 
having a lack of time to consult standard pharmacology textbooks and the lack of a 
reliable internet connection. Also, high cost is an important obstacle to accessing up-
to-date information from journal publications and most recent textbooks 
(Tumwikirize et al., 2007). However, although physicians in developed countries 
have relatively better access to objective sources of information to counterbalance 
what the industry promotes, a Swedish survey has revealed that most GPs miss 
verbal information from non-commercial sources and that they perceive information 
22 
 
differently in terms of what they actually have and what they would like to receive 
(Lundborg et al., 1998).  
GPs generally use the resources that are easily accessible to them in their 
offices. Textbooks are the most preferred means, followed by consulting with 
colleagues and journal articles that are available in their offices. GPs are less likely to 
use medical libraries because of access problems (including the amount of time 
involved), a lack of skill in using catalogues and databases and difficulty in applying 
research literature to clinical situations (Cullen, 1997).  However, use of the Internet 
is undoubtedly increasing. A study conducted among GPs in New Zealand revealed 
that the Internet was ranked higher than medical libraries as a source of information 
(Cullen, 2002). 
 
2.4.3 The role of commercial information sources in prescribing and the 
adoption of a new drug 
Introduction of a new drug usually occurs proactively by means of wide drug 
promotion including a visit by a medical representative and direct one-on-one 
conversations between medical representatives and physicians. Several studies 
reported that the adoption of new drugs had been at the centre of physicians’ interest. 
Anyhow, physicians favouring non-commercial drug information sources (Peay and 
Peay, 1990; Lundborg et al., 1998; Spiller and Wymer, 2001; Layton et al., 2007). 
Despite that, information from commercial sources was received more often than 
information from non-commercial sources (Lundborg et al., 1998). Medical 
representatives represented the most  frequent source  of  information  about  new  
drugs (Strickland-Hodge and Jeqson, 1980; Rohra et al., 2007). Despite what is 
revealed by an Australian study (1984), that MRs were not considered to be a 
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reputable information source, they were still the most often quoted source of 
information about a new drug, and were the major source among others referred to in 
order to prescribe (Peay and Peay, 1984) 
Several studies conducted in UK revealed that while the professional sources 
such as the British National Formulary (BNF), medical journals and consultant’s 
recommendations are used more to evaluate sources about the medical value of a 
new drug, commercial sources such as the Monthly Index of Medical Specialities 
(MIMS), medical  representatives, direct mail industrial material and advertisements 
in medical journals were more often used as source of information which was helpful 
for getting information about whether a medicine exists in the market (Eaton and 
Parish, 1976; Hibberd and Meadows, 1980; Strickland-Hodge and Jeqson, 1980). 
Results similar to those revealed in UK were also obtained from a study conducted in 
Thailand by Layton et al. (2007). However, although the medical representatives 
were considered as being very proficient in offering information about new drugs, 
information obtained from them was perceived by the physicians as likely to be 
biased.  
Also, many studies were conducted to rate the importance of different 
information sources about doctors’ prescribing. Some of those studies rated 
colleagues as the most frequent sources of information, followed by books and 
journals. Also, conferences came before MRs as an important information source in 
rural areas (Verhoeven et al., 1995). Other studies rated information from industry as 
having the highest importance among other sources, and among industry sources; 
while some mentioned MRs as the most important, others listed colleagues, reference 
books, MRs, promotion materials, scientific papers, journals, the internet and 
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products launched in drug promotion forums as possible sources of information with 
no wide differences in their pattern of use (Oshikoya et al., 2011).  
 
 From the above studies it could be concluded that drug promotion in general 
and medical representatives have a specific significant influence on increasing the 
tendency of doctors to prescribe new drugs. Although this influence varies in 
strength and can sometimes be shown to not to be significant, in general it should be 
considered as an important factor in shaping the physicians’ prescribing behaviour 
for new drugs. Also it was found that, with exception of  availability and access to 
up-to-date drug information, no major differences in commercial sources of drug 
information between developed and developing countries. Lack of availability of 
official and scientific sources of information make the physicians in developing 
countries more reliant on commercial sources of information. 
 
2.5 Drug promotion 
Promotion refers to used persuasion tools used by companies to increase the use or 
sales of their products. According to the European Pharmaceutical Market Research 
Association pharmaceutical market research terms and definitions, promotion is 
defined as “the communication with individuals, groups, or organisations to directly 
or indirectly influence audience members attitudes in order to accept/purchase an 
organisation’s products/service” (Lexicon, 1998). The World Health Organization 
(WHO) defines pharmaceutical promotion as “all information and persuasive 
activities by manufacturers and distributors, the effect of which is to induce the 
prescription, supply, purchase and/ or use of medicinal drugs” (Norris et al., 2005). 
